help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwarzenberger, P.
Right arrow Articles by Kolls, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwarzenberger, P.
Right arrow Articles by Kolls, J. K.

Am. J. Respir. Cell Mol. Biol., Volume 19, Number 2, August, 1998 333-337

Antitumor Activity with the HSV-tk-gene-modified Cell Line PA-1-STK in Malignant Mesothelioma

Paul Schwarzenberger, Dinghua Lei, Scott M. Freeman, Peng Ye, Ann Weinacker, Chris Theodossiou, Warren Summer, and Jay K. Kolls

Sections of Hematology/Oncology and Pulmonary/Critical Care, and the Stanley S. Scott Cancer Center Gene Therapy Program, Louisiana State University Medical Center; and Department of Pathology, Tulane University School of Medicine, New Orleans, Louisiana

Malignant mesothelioma (MM) is a thoracic malignancy that is increasing in incidence. Since it is uniformly fatal and kills by local spread, investigators have proposed that MM is a good target for novel treatment approaches, such as gene therapy. We hypothesized that delivery of the HSV-tk gene, using gene-modified tumor cells (PA-1-STK cells), would result in an antitumor effect after treatment with ganciclovir. In in vitro mixing experiments, we found that PA-1-STK cells killed both mouse and human mesothelioma cells in a dose-dependent manner. Moreover, we found that PA-1-STK cells also prolonged survival of mice with MM when the percentage of total tumor cells was high (70%), but observed no survival benefit when the percentage of PA-1-STK cells was low (30%). These data support the rationale for a cell-based gene therapy approach to MM.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
L. H. Harrison Jr, P. O. Schwarzenberger, P. S. Byrne, A. J. Marrogi, J. K. Kolls, and K. E. McCarthy
Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma
Ann. Thorac. Surg., August 1, 2000; 70(2): 407 - 411.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H. I. Pass, B. W. Robinson, J. R. Testa, and M. Carbone
Emerging Translational Therapies for Mesothelioma*
Chest, December 1, 1999; 116(suppl_3): 455S - 460S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. H. Sterman, L. R. Kaiser, and S. M. Albelda
Advances in the Treatment of Malignant Pleural Mesothelioma
Chest, August 1, 1999; 116(2): 504 - 520.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 1998 American Thoracic Society.